Tofacitinib Treatment in Patients With Active COVID-19 Infection

    September 2021 in “ Curēus ”
    Abdulmajeed Alajlan, Lama Alzamil, Amal M Aseri
    Studysummary In this study, two patients with alopecia universalis continued using tofacitinib during active COVID-19 infection and showed no worsening of their illness, despite potential concerns about immunosuppression.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on assets.cureus.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2019

    Related research 1

    1. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018